Flu vaccine brands struggle for recognition even when in fab fighting form
The good news in flu vaccines this year is that they were effective, well-covered by the media and increased sales for several Big Pharmas. The bad news? No one knows their names.
With flu season in full swing, Mitsubishi Tanabe has its eyes on the horizon as it aims to get its quick-to-produce, tobacco-based flu vaccine on the market by 2018 or 2019. Nikkei Asian Review reported on Tuesday that the Osaka-based company has "all but finished" safety and efficacy trials of the vaccine in the U.S. and Canada and plans to run late-stage trials by the end of the year.
J&J; partners with San Diego startup Cue to develop portable HIV viral load Dx
Johnson & Johnson has partnered with Cue to develop a portable, inexpensive and internet-enabled HIV viral load test that would enable physicians in poor countries to more easily determine if a particular drug regimen is effective or not.
South San Francisco-based Vaxart said it has enrolled the first patient in a Phase I trial of the company's oral influenza B vaccine candidate. According to a statement, the vaccine represents the last monovalent component the company needs before it can advance with the development of its quadrivalent influenza vaccine tablet.
Study links use of oral and soap versions of Betadine to lower virus risk
An in vitro research study at Germany's Marburg University found the efficacy of using Betadine as a skin cleanser and a mouthwash version significantly cut the risk of infections by viruses, highlighting a wider public health approach in reducing epidemic risks.
A day after two high-profile organizations announced successful animal results for their own universal flu vaccine, Madison, WI-based FluGen announced a $12 million Series A round to fund the development of its candidate in the race.
The NIAID may have posted 94% efficacy in mice for its investigational "universal" flu vaccine, but The Scripps Research Institute and partner Johnson & Johnson are hot on its heels.
Flu vaccines have grown into a multibillion-dollar business, but researchers at the Ohio State University have published findings that could one day transform the field and put a damper on those figures.
Novavax is making waves in the influenza space, reporting positive Phase II results for its quadrivalent seasonal flu vaccine on Thursday.
A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.